Clinical trials are essential for advancing medical knowledge and improving patient care. However, access to these trials is not equal.individuals in regional,rural,and socially disadvantaged populations often face important barriers to participation,leading to disparities in health outcomes.

To address this issue, decentralized clinical trial (DCT) systems have emerged as a promising solution. DCTs leverage technology and innovative approaches to bring clinical trials to patients, rather than requiring patients to travel to conventional research sites.

The US Food and Drug Governance (FDA) has recognized the potential of DCTs and has developed guidelines to facilitate their implementation. These guidelines encourage the use of telehealth, remote monitoring, and other digital tools to connect patients with researchers and enable participation from anywhere.

Telehealth Integration in Clinical Trials

“Participation in clinical trials improves health outcomes.”

Telehealth plays a crucial role in DCTs by enabling remote consultations, data collection, and patient monitoring.By connecting primary and satellite sites through networked systems, telehealth expands the reach of clinical trials to underserved communities.

This approach not only improves access but also enhances the patient experience by reducing the burden of travel and time commitment. As DCTs become more widespread, they have the potential to transform clinical research and ensure that all populations benefit from medical advancements.